Skip to content
OpenCapital
Get started

Aurinia Pharmaceuticals AUPH Total cash, cash equivalents, restricted cash and short-term investments

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.39B+78.5%
Enterprise value$2.44B+78.3%
P/E8×-25.6×
P/S8×+2.6×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's total cash, cash equivalents, restricted cash and short-term investments.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's total cash, cash equivalents, restricted cash and short-term investments?
Aurinia Pharmaceuticals (AUPH) reported total cash, cash equivalents, restricted cash and short-term investments of $378.78M in Q1 2026.
How has Aurinia Pharmaceuticals's total cash, cash equivalents, restricted cash and short-term investments changed year-over-year?
Aurinia Pharmaceuticals's total cash, cash equivalents, restricted cash and short-term investments increased by 21.1% year-over-year, from $312.9M to $378.78M.
What is the long-term trend for Aurinia Pharmaceuticals's total cash, cash equivalents, restricted cash and short-term investments?
Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's total cash, cash equivalents, restricted cash and short-term investments has grown at a -3.9% compound annual growth rate (CAGR), from $466.08M to $398M.